A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

Around 100 million Africans live in onchocerciasis endemic areas. Control of onchocerciasis as a public health problem and possibly even elimination of onchocerciasis infection relies on annual community-directed mass treatment with ivermectin. Given concerns about possible emergence of ivermectin r...

Full description

Bibliographic Details
Main Authors:	Awadzi, Kwablah, Opoku, Nicholas O., Attah, Simon K., Lazdins-Helds, Janis, Kuesel, Annette C.
Format:	Online
Language:	English
Published:	Public Library of Science 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072596/

id	pubmed-4072596
recordtype	oai_dc
spelling	pubmed-40725962014-07-02 A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection Awadzi, Kwablah Opoku, Nicholas O. Attah, Simon K. Lazdins-Helds, Janis Kuesel, Annette C. Research Article Around 100 million Africans live in onchocerciasis endemic areas. Control of onchocerciasis as a public health problem and possibly even elimination of onchocerciasis infection relies on annual community-directed mass treatment with ivermectin. Given concerns about possible emergence of ivermectin resistance of the parasite Onchocerca volvulus and elimination of infection in areas where very high numbers of vectors can result in continued parasite transmission even when only few parasites are present in only a few people, research for drugs with higher effect on the parasite remains important. A series of non-clinical and clinical studies was planned to find out whether moxidectin, a veterinary anthelminthic, is sufficiently safe for mass treatment and has a better effect on the parasite than ivermectin. We report here results from the first study in infected people conducted to assess in small numbers of individuals the adverse reactions to the killing of parasites by moxidectin. A single dose of 8 mg moxidectin reduced skin parasite numbers better and for a longer time than ivermectin. The frequency and severity of adverse reactions was so low that a larger study to better characterize the adverse reactions to moxidectin and compare its efficacy with that of ivermectin was initiated. Public Library of Science 2014-06-26 /pmc/articles/PMC4072596/ /pubmed/24968000 http://dx.doi.org/10.1371/journal.pntd.0002953 Text en © 2014 World Health Organization http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Awadzi, Kwablah Opoku, Nicholas O. Attah, Simon K. Lazdins-Helds, Janis Kuesel, Annette C.
spellingShingle	Awadzi, Kwablah Opoku, Nicholas O. Attah, Simon K. Lazdins-Helds, Janis Kuesel, Annette C. A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
author_facet	Awadzi, Kwablah Opoku, Nicholas O. Attah, Simon K. Lazdins-Helds, Janis Kuesel, Annette C.
author_sort	Awadzi, Kwablah
title	A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
title_short	A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
title_full	A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
title_fullStr	A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
title_full_unstemmed	A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection
title_sort	randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in onchocerca volvulus infection
description	Around 100 million Africans live in onchocerciasis endemic areas. Control of onchocerciasis as a public health problem and possibly even elimination of onchocerciasis infection relies on annual community-directed mass treatment with ivermectin. Given concerns about possible emergence of ivermectin resistance of the parasite Onchocerca volvulus and elimination of infection in areas where very high numbers of vectors can result in continued parasite transmission even when only few parasites are present in only a few people, research for drugs with higher effect on the parasite remains important. A series of non-clinical and clinical studies was planned to find out whether moxidectin, a veterinary anthelminthic, is sufficiently safe for mass treatment and has a better effect on the parasite than ivermectin. We report here results from the first study in infected people conducted to assess in small numbers of individuals the adverse reactions to the killing of parasites by moxidectin. A single dose of 8 mg moxidectin reduced skin parasite numbers better and for a longer time than ivermectin. The frequency and severity of adverse reactions was so low that a larger study to better characterize the adverse reactions to moxidectin and compare its efficacy with that of ivermectin was initiated.
publisher	Public Library of Science
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072596/
_version_	1612106783395938304

A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

Similar Items